Discontinuing β-blockers after one year or longer is noninferior for all-cause death, recurrent MI, or hospitalization for heart failure.

Background: Atrial fibrillation (Afib) that occurs after a successful atrial flutter (AFL) ablation may negate the potential benefits of the ablation. Afib occurs more often when severe left ...

The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary ...

Trial assessed outcomes of quitting therapy after 1 year among select MI survivors ...

Please provide your email address to receive an email when new articles are posted on . Subclinical left ventricular abnormalities in SSc impact survival and increase dyspnea risk. LV ejection ...

ENTRESTO The FDA has approved Entresto for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. The Food and Drug ...

Because life expectancy and the prevalence of risk factors such as hypertension, obesity and diabetes are rising globally, heart failure (HF) is growing into a major health problem. Impairment of left ...

The debate on the link between hypertension and systolic heart failure has been re-examined often and many such considerations are contained in pertinent reviews of the epidemiology, for example by ...